



**The ONTARGET® Trial Program
(n=31,546)**

ONTARGET®
principal trial
n=25,620

- To compare the efficacy of PRITOR®/KINZAL® vs. ramipril in preventing CV morbidity and mortality
- To determine any additional benefit of combining PRITOR®/KINZAL® with ramipril

Results published April 2008

TRANSCEND®
parallel trial
n=5,926

To compare the efficacy of PRITOR®/KINZAL® vs. placebo on top of standard therapy in preventing CV morbidity and mortality in patients intolerant to ACE inhibitors


Results published August 2008

Acronyms: ACE – angiotensin-converting enzyme, CV – cardiovascular
The ONTARGET Investigators. *N Engl J Med* 2008;358:1547-59.
The TRANSCEND Investigators. *Lancet* 2008. Epub ahead of print.





ONTARGET®: the world's largest ARB morbi-mortality trial (n=25,620)



Acronyms: ACE - angiotensin-converting enzyme, ARB - angiotensin II receptor blocker, CV – cardiovascular, BP – blood pressure


The ONTARGET Investigators. *N Engl J Med* 2008;358:1547-59.

The TRANSCEND Investigators. *Lancet* 2008. Epub ahead of print.






Pritor[®]/Kinzal[®]: proven broad protection





The ONTARGET[®] Trial Program

Substudies



Yusuf S., *Am J Cardiol* 2002;98(suppl):18A–26A; Unger T., *Am J Cardiol* 2003;91 (suppl):28G–34G; Zimmerman M. & Unger T., *Expert Opin Pharmacother* 2004;5:1201–1208.